HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.

Fountzilas, George

HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. [electronic resource] - Journal of translational medicine Jan 2012 - 10 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1479-5876

10.1186/1479-5876-10-10 doi


Adult
Aged
Antibiotics, Antineoplastic--pharmacology
Antigens, Neoplasm--genetics
Breast Neoplasms--drug therapy
Chemotherapy, Adjuvant
DNA Topoisomerases, Type II--genetics
DNA-Binding Proteins--genetics
Dose-Response Relationship, Drug
Epirubicin--pharmacology
Female
Gene Expression Profiling
Gene Expression Regulation, Neoplastic--drug effects
Genes, Neoplasm--genetics
Humans
Ki-67 Antigen--metabolism
Middle Aged
Multivariate Analysis
Paraffin Embedding
Poly-ADP-Ribose Binding Proteins
Proportional Hazards Models
RNA, Messenger--genetics
Receptor, ErbB-2--genetics
Receptors, Estrogen--metabolism
Receptors, Progesterone--metabolism
Risk Factors
Tissue Fixation
Treatment Outcome
Young Adult